News

Business Wire2y
Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First ...
The financing will fund the planned Phase 3 trials for Apnimed’s lead candidate, AD109 (aroxybutynin + atomoxetine), that has the potential to be the first oral treatment for OSA. Enrollment for ...
Yahoo Finance1y
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 ...
Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate ... with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia ...